# A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

> **NCT06631989** · PHASE1,PHASE2 · RECRUITING · sponsor: **Wayshine Biopharm, Inc.** · enrollment: 100 (estimated)

## Conditions studied

- EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** WSD0922-FU

## Key facts

- **NCT ID:** NCT06631989
- **Lead sponsor:** Wayshine Biopharm, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-04
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06631989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06631989, "A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06631989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*